Dr. Travis E. Grotz, M.D.

Claim this profile

Mayo Clinic in Rochester

Studies Peritoneal Cancer
Studies Stomach Cancer
4 reported clinical trials
13 drugs studied

Area of expertise

1

Peritoneal Cancer

Travis E. Grotz, M.D. has run 3 trials for Peritoneal Cancer. Some of their research focus areas include:

Stage IV
KRAS positive
CEA positive
2

Stomach Cancer

Travis E. Grotz, M.D. has run 2 trials for Stomach Cancer. Some of their research focus areas include:

Stage IV
CEA positive
CA 19-9 positive

Affiliated Hospitals

Image of trial facility.

Mayo Clinic In Rochester

Clinical Trials Travis E. Grotz, M.D. is currently running

Image of trial facility.

Immunotherapy + Chemotherapy

for Stomach Cancer

This phase Ib trial test effects of aldesleukin in combination with nivolumab and standard chemotherapy in treating patients with gastric cancer that has spread to the tissue lining of the abdomen (peritoneal metastasis). Aldesleukin is similar to a protein that naturally exists in the body that stimulates the immune system to fight infections. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as leucovorin calcium, fluorouracil, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving aldesleukin in combination with nivolumab and standard chemotherapy may work better in treating patients with gastric cancer with peritoneal metastasis.

Recruiting

1 award

Phase 1

Image of trial facility.

Robotic Surgery + HIPEC

for Stomach Cancer

This phase II clinical trial tests how well robotic cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in treating patients with gastric cancer that has spread to the tissue that lines the wall of the abdominal cavity (peritoneum). Gastric cancer is the third leading cause of cancer related deaths worldwide and peritoneal metastasis are found in 30% of patients at time of diagnosis. Patients with peritoneal metastasis have poor survival rates. Traditional surgery is done with a large incision and has a high complication rate and longer hospital stays. Robot assisted (robotic) cytoreduction is a surgical option that uses small incisions and there is less risk of complications. HIPEC involves infusing heated chemotherapy into the abdominal cavity during surgery. Robotic cytoreduction together with HIPEC may improve recovery and decrease complications after surgery.

Recruiting

1 award

Phase 2

More about Travis E. Grotz, M.D.

Clinical Trial Related

2 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 4 Active Clinical Trials

Treatments Travis E. Grotz, M.D. has experience with

  • Cisplatin
  • Hyperthermic Intraperitoneal Chemotherapy
  • Minimally Invasive Proximal Gastrectomy
  • Total Gastrectomy
  • Mitomycin
  • Nab-paclitaxel

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Travis E. Grotz, M.D. specialize in?

Is Travis E. Grotz, M.D. currently recruiting for clinical trials?

Are there any treatments that Travis E. Grotz, M.D. has studied deeply?

What is the best way to schedule an appointment with Travis E. Grotz, M.D.?

What is the office address of Travis E. Grotz, M.D.?

Is there any support for travel costs?